Use of antibodies capable of blocking human thyroid-stimulating hormone receptor to treat hyperthyroidism and endocrine orbitopathy

摘要

Antibodies capable of blocking human thyroid-stimulating hormone (hTSH) receptor, or specifically binding fragments of such antibodies, are used to treat: (a) hyperthyroidism ascribable to: (i) autoantibodies that stimulate the hTSH receptor (Basedow's disease); (ii) overstimulation of the thyroid gland by endogenous TSH; or (iii) activating mutations of the hTSH receptor; and (b) endocrine orbitopathy. An Independent claim is also included for monoclonal antibodies produced by hybridoma cell lines 4E9/B2/C1 (DSM ACC2389), 4C1/E1/G8 (DSM ACC2390), 1B1/E10/B11/C12 (DSM ACC2391), 7E3/F8/E3 (DSM ACC2392) and 3H10/A11/A1 (DSM ACC2393).